Biogen (BIIB) Misses Q4 EPS by 23c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Biogen (BIIB) falls as earnings, revenue misses consensus
February 13, 2024 7:24 AM ESTBiogen (NASDAQ: BIIB) shares are down more than 5% premarket Tuesday after the company reported earnings for its latest quarter, missing the consensus profit and revenue estimate.
The biotechnology firm reported fourth-quarter earnings of $2.95 per share, $0.23 worse than the analyst estimate of $3.18.... More
